ESMO 2019 — Advanced ovarian cancer: adding olaparib to bevacizumab prolongs progression-free survival


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Following first-line platinum-based chemotherapy, patients with newly diagnosed advanced ovarian cancer had significantly improved progression-free survival (PFS) with the addition of olaparib, as compared to bevacizumab, the current standard of care.

Why this matters

  • First phase 3 trial to evaluate efficacy and safety of a PARP inhibitor plus bevacizumab as first-line maintenance therapy in advanced ovarian cancer not restricted by surgical outcome or BRCA mutation status.

Study design

  • PAOLA-1/ENGOT-ov25 was a double-blind, international phase 3 trial with 806 patients in complete or partial response following platinum-based chemotherapy plus bevacizumab.
  • Randomisation (2:1) to olaparib 300 mg twice daily for up to 24 months or placebo plus bevacizumab at 15 mg/kg on day 1 every 3 weeks for 15 months.
  • These interim results were based on an analysis of 59% of the data.
  • Funding: Arcagy Research, AstraZeneca, MSD, and Hoffmann-La Roche.

Key results

  • After a median follow-up of 24.0 months (olaparib) and 22.7 months (placebo), PFS was 22.1 months vs 16.6 months (HR 0.59; P
  • Superiority of olaparib was more pronounced among patients with BRCA mutations (HR 0.31; 95% CI 0.20-0.47) than without (HR 0.71; 95% CI 0.58-0.88) but statistically significant for both groups.
  • PFS with olaparib vs placebo was also superior in patients who were HRD-positive (HR 0.33; 95% CI 0.25-0.45), but not in those with negative or unknown HRD status (HR 0.92; 95% CI 0.72-1.17).
  • 20% discontinuation rate for adverse events is the highest reported from all trials of PARP inhibitors (placebo: 6%).

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit